/NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR
DISSEMINATION TO U.S. NEWS WIRE SERVICES/
TSX VENTURE SYMBOL: APZ
MONTREAL, June 20 /CNW Telbec/ - Aptilon Corporation (TSX VENTURE:APZ)
("Aptilon" or the "Corporation") announced today that it has filed a
preliminary short form prospectus with the securities regulatory authorities
in Alberta, British Columbia, Quebec and Ontario in connection with a best
efforts offering of common shares of the Corporation (the "Offering"). The net
proceeds of the Offering are for working capital and for general corporate
purposes, including acquisitions.
The Offering will be led by Paradigm Capital Inc. with a syndicate
comprised of Loewen, Ondaatje, McCutcheon Limited. and Cormark Securities Inc.
(collectively, the "Agents"). Final pricing and determination of the number of
common shares to be sold pursuant to the Offering will occur immediately prior
to the filing of the (final) short form prospectus in respect of the Offering.
The Offering is subject to regulatory approval including approval of the
TSX Venture Exchange.
This press release is not an offer to sell or the solicitation of an
offer to buy the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to qualification or registration
under the securities laws of such jurisdiction. The securities being offered
have not been, nor will they be, registered under the United States Securities
Act of 1933, as amended, and such securities may not be offered or sold within
the United States or to, or for the account or benefit of, U.S. persons absent
registration or an applicable exemption from U.S. registration requirements.
Aptilon enables pharmaceutical, biotech, and medical device companies to
effectively reach and interact with physicians via the Internet through its
innovative live video detailing (with company reps), e-detailing, e-sampling,
peer selling, and other educational content programs. Leading healthcare
companies have adopted Aptilon's "Sales Force of the Future" model, driving
tens of thousands of high-quality rep-physician interactions averaging 8 to 10
minutes in length. Aptilon provides the necessary infrastructure for sales
representatives to build physician awareness, understanding, and preference
during all stages of a product life cycle, from pre-launch education through
to end-stage support. For more information, visit www.aptilon.com.
This news release contains forward-looking information. These statements
relate to future events or future performance and reflect management's current
expectations and assumptions. Such forward-looking statements reflect
management's current beliefs and are based on information currently available
to management of Aptilon. A number of factors could cause actual events,
performance or results to differ materially from the events performance and
results discussed in the forward-looking statements. These forward-looking
statements are made as of the date hereof and Aptilon does not assume any
obligation to update or revise them to reflect new events or circumstances.
For further information:
For further information: Denis Martineau, President, Aptilon, (514)
844-8866 xt 228, firstname.lastname@example.org; Media Relations: Alexandra Malka,
Aptilon, Marketing Communication Specialist, (514) 844-8866 xt 239,